Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2011

View Archived Issues

Anti-HIV antibody response at mucosal sites protects monkeys against infection

Roskamp Institute obtains IRB approval for study of RCP-006 in humans

IQ Therapeutics begins phase I trial of IQ-DAA for anthrax

Expression of bone morphogenetic protein 7 predicts clinical outcome in gastric cancer

Autoantibodies against tyrosine 3-monooxygenase are increased in patients with generalized vitiligo

Ganetespib is active in NSCLC and set to enter phase IIb/III trial in combination with docetaxel

GS-7340 is more effective than TDF in reducing HIV-1 RNA in patients

Pharmacyclics suspends development of tyrosine-protein kinase BTK inhibitor PCI-45292

Merck KGaA discloses novel protein kinase inhibitors

Merz presents new modulators of metabotropic glutamate mGlu5 receptor

Bavarian Nordic joins Danish research project to develop anticancer vaccines

New metal chelators presented by FerroKin

New glucocorticoid receptor ligands patented by Karo Bio and Zydus-Cadila

Targacept and GSK terminate strategic alliance

FDA accepts for review Lundbeck's NDA for clobazam in Lennox-Gastaut syndrome

GlaxoSmithKline submits MAA in Europe for Nimenrix meningitis vaccine

Novartis synthesizes new inhibitors of hepatocyte growth factor receptor

DURATION-6 trial of diabetes therapy Bydureon misses primary endpoint

Eisai receives FDA approval for Banzel oral suspension

European Commission grants orphan drug status to ThermoDox in primary liver cancer

Cell Therapeutics meets with FDA to appeal decision on pixantrone

DiaMedica's DM-204 reduces hypertension in animal models

Ceplene/IL-2 combination improves survival of patients with AML of monocyte origin

Allos and FDA reach SPA agreement for phase III trial of Folotyn in peripheral T-cell lymphoma

Cellceutix reports new data on anticancer drug Kevetrin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...